136 results about "Prophylactic treatment" patented technology

The invention belongs to the technical field of medicines, and discloses a substituted oxadiazole-aniline compound, a preparation method thereof, a pharmaceutical composition taking the compound as an active component, and application of the substituted oxadiazole-aniline compound and the pharmaceutical composition in treatment and / or prevention of infectious diseases caused by coronavirus. Specifically, the invention relates to a compound shown as a formula (I) and an isomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the compound disclosed by the invention, and R1, R2, R3, R4 and n are described in the specification. The invention aims to prepare a new compound with anti-coronavirus activity, and the new compound can be used as a potential new drug for treatment or prophylactic treatment of infectious diseases caused by viruses, especially pneumonia diseases caused by coronaviruses. # imgabs0 #

Systems and methods of predicting future medical events are based on the processing of medical images. The prediction of premature birth and estimation of gestational age based on ultrasound images are presented as illustrative examples. The new abilities to estimate the probability of future medical events, before they otherwise could be predicted, provides new avenues for the development of preventative treatments.

The present disclosure provides a method and system for forecasting the likelihood of seizure onset within an individual. Specifically, the present disclosure relates to an intracranial implant comprising one or more electrodes attached thereto and an associated method for delivering active perturbation patterns to brain regions which includes: sending, via the intracranial implant, an electrical stimuli into a brain, wherein the electrical stimuli is sent in accordance with a stimuli pattern; measuring an output from the brain in response to the electrical stimuli; feeding the output into a forecasting model; and detecting, via the forecasting model, outputs that indicate a high likelihood of seizure. The intracranial implant and associated method may further apply via the brain-contacting electrodes, a prophylactic treatment to the brain to prevent a seizure from occurring, based on detecting an output indicating a high likelihood of seizure.

The present disclosure provides a compound for use in therapeutic and / or prophylactic treatment of non-alcoholic steatohepatitis (NASH) and / or alcoholic steatohepatitis (ASH). The compound for use according to the invention, is an unsaturated fatty acid with an oxygen incorporated in the β-position, and further comprising an α-substituent. More particularly, the invention provides a compound for use in treatment of NASH and / or ASH, and a method using this, wherein the compound is of Formula (II), wherein R1, R2, R3, X, and Y are as defined in the specification; and wherein this compound may be administered alone or in combination with an additional active agent.

In an embodiment, a system for of preventively treating hypoglycemia includes a continuous glucose monitoring (CGM) sensor system configured to generate measurements associated with a current glucose level of a patient. The system further includes one or more memories comprising executable instructions and one or more processors in data communication with the one or more memories. The one or more processors are configured to execute the executable instructions to receive, from the CGM sensor system, one or more measurements associated with the current glucose level of the patient and compute a sequence of preventive hypoglycemia treatments over a future time period based on the one or more measurements and a prediction of glucose control to be produced by the sequence. The one or more processors are further configured to prompt the patient with a first preventive hypoglycemia treatment in the sequence of preventive hypoglycemia treatments.

Insulin therapy revolutionized the care of patients with diabetes, yet insulin-induced hypoglycemia remains a serious life-threatening complication of insulin therapy. Glucagon is a highly effective treatment for hypoglycemia; however, current dosage forms remain under-utilized due to poor patient compliance. High-density, readily soluble, and thermostable solid glucagon formulations applied with painless, application-specific microneedle-patches can treat hypoglycemia in type 1 diabetes patients who are awake or asleep. On-demand patches can prevent or treat mild hypoglycemia during the day, and enzyme-driven hypoglycemia-responsive patches can release glucagon autonomously during the night. These patches have excellent in vitro glucagon stability, loading, and release kinetics and can treat hypoglycemia in diabetic humans and animals. These delivery systems enable new modes of glucagon therapy, thereby expanding the clinical role of glucagon beyond the emergency setting.

A composition and method for therapeutic or prophylactic treatment of mammals includes a mixture of IgY antibodies derived from one or more eggs laid by one or more avian species, wherein each of the one or more avian species have been vaccinated with one or more of the plurality of antigens. The mixture of IgY antibodies can be combined with a protective material that includes colostrum. In some embodiments the composition can also include IgA and IgM antibodies.

The present application relates to novel immunotherapeutic compositions and uses thereof. The present invention relates generally to an immunotherapeutic composition. More specifically, the present invention relates to an immunotherapeutic composition that immunointeracts with T lymphocytes in a subject suffering from peanut allergy or allergy to other tree nuts. Such compositions preferably react immunologically with T cells in a subject suffering from an allergy to an Ara h 1 and / or Ara h 2 allergen. The compositions of the present invention are useful in the therapeutic or prophylactic treatment of conditions characterized by an abnormal, improper or otherwise unwanted immune response to peanut, Ara h1 and / or Ara h2, or a derivative or homolog thereof.

The invention belongs to the field of chemical synthesis, and relates to a GSTO1 inhibitor and application thereof, and application of the compound in medicines for treating or prophylactically treating diseases related to GSTO1, in particular to a compound shown as a formula I, or an isomer thereof, or pharmaceutically acceptable salt thereof and application thereof, and substituent groups in the formula I are as defined in the specification.

Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.

The present invention provides therapeutic and / or prophylactic treatments against leishmaniasis in non-human mammals in need of such treatment, said treatments comprising administering oleyl phosphocholine to said non-human mammal. The invention also relates to veterinary (pharmaceutical) compositions adapted, suitable and / or intended for use in these treatments.

The present invention belongs to the field of medical technology, discloses substituted pyrrole-2,5-dione compounds and preparation methods and uses thereof, relates to pharmaceutical compositions in which the compounds are active ingredients, and their applications in treating and / or preventing infectious diseases caused by Mycobacterium tuberculosis. Specifically, the present invention relates to a compound shown in formula (I), a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the compound of the present invention, wherein R1, R2, and R3 are as described in the specification. The present invention aims to prepare a new compound having anti-mycobacterium tuberculosis activity, which, as a potential new drug, can be used for infectious diseases caused by bacteria, particularly for the treatment or preventive treatment of pulmonary tuberculosis (TB) diseases caused by Mycobacterium tuberculosis.

The present invention provides a method of therapeutic or prophylactic treatment of microvascular brain disease in a subject comprising orally administering to the subject a reduced form of a compound comprising methylthionine (MT) wherein the administration provides the subject with 8 to 200 mg MT per day, optionally divided into two or more doses.

Provided herein are the methods of using an anti-inflammatory agent for prophylactic therapy to prevent or alleviate CRS and / or NE associated with therapeutic interventions, such as the administration of a nucleic acid encoding a CAR.

The invention relates, in part, to a method for the prophylactic treatment of a coronavirus infection in a human adult subject comprising administering at least two doses of a Bacillus Calmette-Guerin (BCG) vaccine to the subject, wherein the subject is a type I diabetic.

Methods of reducing skin fibrosis by prophylactically treating skin prior to radiation therapy are described herein. The methods include applying an effective amount of DFO to skin that may be subjected to radiation, e.g., during treatment for cancer at a treatment site. The DFO may be administered transdermally.

Embodiments described herein generally relate to methods and apparatus for adjusting and / or controlling body temperature and / or the flow of blood within blood vessels within a mammal. Embodiments of the present disclosure may further provide a therapeutic method for acute and preventive treatment of a migraine headache or other recurrent acute or chronic pain of a user, comprising: applying a vacuum to a portion of a body of a user and circulating warmed water over a surface of the portion of the body of the user, wherein applying the vacuum and circulating the warmed water is configured to overcome a vasoconstricted state of the portion of the body and manipulate blood flow to a head and / or distal appendages of the user.

The invention discloses a group of biomarkers for predicting preventive response of gout patients to colchicine and application of the biomarkers, and relates to the technical field of biomedicine. The marker provided by the invention comprises Sm d42: 3, Cis-13-docosenic acid (erucic acid), Creatinine (creatinine), Gitoxin (hydroxydigitonin) and Trichosanic acid (tricosic acid). The invention also provides a kit and a detection system which are prepared by applying the marker and are used for predicting the preventive response of the gout patient to colchicine. Through the biomarker, the kit and the prediction system, whether the colchicine is effective in preventing gout attack can be accurately predicted, and more accurate preventive treatment is facilitated.

The application discloses application of an immune checkpoint inhibitor. One of the applications is the application in the preparation of a drug for preventing and treating cancer in a subject. The embodiments of the application show that the application of the immune checkpoint inhibitor to the early cancer stage (high-grade intraepithelial neoplasia stage (HGIN)) of esophageal squamous cell carcinoma can reverse the progression of esophageal squamous cell carcinoma lesions, effectively control the recurrence and metastasis of cancer.

The present invention relates to a DHP-I inhibitor for use in a method for the prophylactic and / or therapeutic treatment of a neuroinflammatory disease. In some embodiments, it relates to a DHP-I inhibitor for use in a method for the prophylactic treatment of neurodegeneration. The present invention also relates to a DHP-I inhibitor for use as neuroprotectant. It further pertains to related methods for the prophylactic and / or therapeutic treatment of a neuroinflammatory disease and the use of a DHP-I inhibitor in the manufacturing of a medicament for use in these methods. The present invention also provides pharmaceutical compositions and delivery systems for use in the methods of the invention, as well as to a pharmaceutical composition or drug delivery systems suitable for administration by a route bypassing the blood brain barrier (BBB) and / or the blood retinal barrier (BRB), preferably selected intrathecal, intracranial, intranasal and / or ocular administration; or suitable for trespassing the BBB and / or the BRB.

Compositions and principles for use before parturition in the prophylactic treatment of hypocalcemia in ruminant animals include compositions having phosphate binders for the prophylactic treatment of parturient hypocalcemia in ruminant animals. These compositions are presented in unit dosage forms, with one or more doses administered daily to the gastrointestinal tract of the ruminant animal, or in wet form. The composition contains one or more phosphate binders and one or more nutrients selected from minerals, vitamins, and amino acids, as well as a composition that includes an inhibitor of the small intestinal Na-phosphate transporter for the prophylactic treatment of parturient hypocalcemia in ruminant animals. Phosphate binders are selected from aluminum, iron, sevelamer, and lanthanum salts, with either inorganic or organic acids, hydrates thereof, or any mixture thereof.

The present invention describes a (first) anti-HSV antibody or antigen-binding fragment thereof that binds to glycoprotein B (gB) of HSV-1 and / or HSV-2 wherein the antibody comprises complementarity determining regions VHCDR1, VHCDR3, VLCDR1, VLCDR2 and VLCDR3, each comprising a sequence defined in the claims wherein the antibody or antigen-binding fragment has a sequence of at most 5.0 x 10 <-4 > s <-1 >, preferably at most 1.0 x 10 <-4 > s <-1 >, preferably at most 1.0 x 10 <-4 > s <-1 >, preferably at most 5.0 x 10 <-4 > s <-1 >, preferably at most 1.0 x 10 <-4 > s <-1 >, preferably at most 1.0 x 10 <-4 > s <-1 >, preferably at most 1.0 x 10 a low dissociation rate kdis of up to 5.0 x 10 <-5 > s <-1 > and most preferably up to 2.9 x 10 <-5 > s <-1 >. In addition, the present invention also describes a combination of (A) the (first) anti-HSV antibody or antigen-binding fragment thereof; and (B) a second anti-HSV antibody or antigen-binding fragment thereof that recognizes / binds to glycoprotein B (gB) of HSV-1 and / or HSV-2 wherein the antibody comprises complementarity determining regions VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2 and VLCDR3, each comprising the sequences defined in the claims wherein the second antibody has a dissociation constant Kd of at most 40 nM, preferably at most 30 nM, more preferably at most 20 nM, even more preferably at most 15 nM, at most 13 nM and at most 10 nM. Furthermore, the present invention also describes a pharmaceutical composition comprising an effective amount of said anti-HSV antibody or antigen-binding fragment thereof, or a combination of said antibodies, and at least one pharmaceutically acceptable excipient. Furthermore, the present invention also describes an anti-HSV antibody or antigen binding fragment thereof or said combination of said antibodies for use in a method of prophylactic or therapeutic treatment of a disorder or disease as defined in the claims. Furthermore, the present invention also describes a bispecific antibody that binds to glycoprotein B (gB) of HSV-1 and / or HSV-2, comprising: (A) a first binding domain comprising: complementarity determining regions VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2 and VLCDR3 of the aforementioned first antibody; and (B) a second binding domain comprising: complementarity determining regions VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, and VLCDR3 of the aforementioned second antibody; wherein the bispecific antibody has a low dissociation rate kdis of at most 5.0 x 10 <-4 > s <-1 >, preferably at most 1.0 x 10 <-4 > s <-1 >, at most 5.0 x 10 <-5 > s <-1 >, most preferably at most 2.9 x 10 <-5 > s <-1 >. Finally, the present invention describes a trispecific antibody comprising a third binding domain in addition to the first binding domain and the second binding domain as described for the bispecific antibody.

The invention relates to antigen-binding polypeptides comprising the CDR1, CDR2 and CDR3 region of a VHH domain of a camelid heavy chain antibody. The polypeptides bind specifically to CD229 and are therefore suitable for the diagnosis as well as for the therapeutic and prophylactic treatment of diseases characterised by increased CD229 expression. Fusion proteins, conjugates and pharmaceutical compositions comprising the antigen-binding polypeptides are also disclosed. In addition, the invention relates to the use of such antigenbinding polypeptides in methods for detecting CD229 or CD229-expressing cells in a biological sample. Methods for purifying and concentrating CD229 or CD229-expressing cells using the antigen-binding polypeptides are also described.

The invention discloses application of a let-7e inhibitor loaded on nano-vesicles derived from bone marrow mesenchymal stem cells in preventive treatment of postmenopausal osteoporosis, and belongs to the technical field of biological medicines. According to the invention, the let-7e inhibitor is designed and synthesized and is'neutralized ', so that the inhibition of the let-7e inhibitor on an osteogenic gene is relieved, the osteogenic function of osteoblasts is promoted, and meanwhile, the nano-vesicles which are derived from mesenchymal cells and have an anti-inflammatory effect are selected as a delivery tool of the let-7e inhibitor to prevent and treat osteoporosis. Experimental results indicate that the mouse bone marrow mesenchymal stem cell-derived nano-vesicle loaded with the let-7e inhibitor has a good preventive treatment effect on mouse osteoporosis after ovariectomy. A stem cell nano-vesicle treatment platform based on mouse bone marrow mesenchymal stem cell-derived nano-vesicles loaded with let-7e inhibitors is expected to be developed into a novel clinical intervention scheme for preventing postmenopausal osteoporosis.

Provided herein include compounds, compositions, kits and methods for preventing and treating psychiatric disorders. The composition and methods described herein can prophylactically treat a subject prior to and / or after a stressor and / or prior to the recurrence of a stressor, thereby preventing or delaying a relapse of depression or depression-like and / or stress-induced behaviors and disorders. The composition can comprise a serotonin 4 receptor (S-HUR) agonist and an N- methyl-D-aspartate (NMDAR) antagonist and a pharmaceutically acceptable salt, analog, derivative or metabolite thereof.

The present invention relates to a composition comprising a transfection agent and an mRNA encoding at least one human endogenous retroviral (HERV) envelope protein or an immunogenic portion thereof, with a mutation in the immunosuppressive domain (ISD) that reduces its immunosuppressive properties. The invention also relates to the use of this composition in the manufacture of medicaments and in therapeutic and prophylactic treatments.

The present invention provides novel methods for treating and preventing colorectal cancer in a subject by administering a composition comprising β-galactosidase, a bacterial culture capable of producing β-galactosidase, such as an S. thermophilus culture, or a fraction of the culture comprising β-galactosidase. A kit useful for such methods is also provided. In addition, the present invention provides a composition for treating or preventing colon cancer.

The present invention relates to an H LA tumor antigen polypeptide comprising a cell-penetrating peptide (HTAPP-CPP) use as a medicament in the therapeutic and prophylactic treatment of carcinomas. The HLA tumor antigen polypeptide comprises a cell-penetrating peptide (HTAPP-CPP) and further comprises HLA tumor antigen peptides (HTAP) associated with MHC class I and / or class II complexes, arranged on at least one HLA tumor antigen polypeptide (HTAPP). These HTAP are tumor-specific or tumor-associated. The HLA tumor antigen polypeptide (HTAPP) is provided as a tandem polypeptide or an overlapping tandem polypeptide, both comprising at least 2 HLA tumor antigen peptides corresponding to MHC class I and / or class II complexes. This invention further comprises a method for determining an pharmaceutical composition comprising HLA tumor antigen polypeptide(s), a method for preparing a formulation according to the invention, and the use of a composition and formulation according to the invention for the preparation of a pharmaceutical composition.

The present application relates to a kind of protein combination, kit and system for predicting secondary infection of hepatitis B related liver failure patient, including the use of protein combination in the preparation for predicting secondary infection of hepatitis B related liver failure patient, the combination includes lysozyme LYZ, calmodulin 1 CALM1, heparin cofactor II SERPIND1 and cutin DPT.It is directly reflected that the combination is biomarker "inflammation-coagulation imbalance" this core mechanism of liver disease secondary infection, with high specificity, and the combination is not interfered by liver disease background, more can truly reflect the potential reaction state of body to infection under liver disease background, to overcome the problem of "failure" and "false negative" of traditional index ";The combination can significantly change concentration when patient is admitted to hospital early, without clinical infection signs, to provide key time window for early preventive treatment.

A method of detecting the risk of biofilm development comprising: taking a blood sample from a patient; analysing the blood sample by performing human leukocyte antigen (HLA) genotyping; determining i